Why Doctors and AI Should Drive Treatment, Not Insurers
A push for digital health records argues that AI diagnostic tools and physicians—not insurers—should control patient care decisions.
A growing chorus of health experts and technologists is arguing that the authority to determine patient treatment plans belongs squarely with physicians and artificial intelligence tools—not with health insurance companies whose financial incentives can conflict with optimal care. The debate has sharpened as insurer prior-authorization denials draw increasing scrutiny from patients, lawmakers, and clinicians alike.
At the center of the argument is the digital health record: a comprehensive, unified view of a patient's full medical history that clinicians could access in real time. Proponents say that when AI-driven diagnostic tools are layered on top of such records, the combination gives doctors far richer context for clinical decisions than the fragmented, paper-based or siloed systems that still dominate much of American healthcare today.
Read more CZ Pushes to Make the United States the Global Crypto Capital →
The core critique is structural. Insurers currently wield significant gatekeeping power through prior-authorization requirements, which critics contend delay or deny medically necessary care based on cost calculations rather than clinical evidence. Shifting that decision-making authority to physicians supported by AI, the argument goes, would realign incentives around patient outcomes rather than premium savings.
AI's role in this vision is not to replace physician judgment but to augment it—surfacing patterns across a patient's longitudinal record that a busy clinician might miss, flagging drug interactions, or highlighting evidence-based treatment pathways. That kind of decision support, backers argue, is categorically different from an insurer's algorithm trained to minimize payouts.
The debate lands at a pivotal moment, as federal policymakers weigh rules on prior authorization transparency and the health-tech industry accelerates investment in clinical AI platforms. Whether the healthcare system rebalances power away from insurers toward clinicians and technology remains an open and consequential question. Continue reading at MarketWatch.com
